Evolus (EOLS) Scientific Investor presentation summary

Differentiated product portfolio

• Portfolio includes a fast-growing neurotoxin (Jeuveau) and the first new HA gel technology in a decade (Evolysse), both designed for high patient satisfaction and safety.

• Profhilo, a leading skin quality injectable in Europe, expands the offering into a third vertical, addressing hydration and elasticity.

• Evolysse HA gels use Cold-X technology, preserving HA structure and requiring less cross-linking agent, resulting in efficient, natural-feeling gels.

Clinical performance and safety

• Jeuveau demonstrated non-inferiority and similar safety to Botox in Phase III head-to-head studies, with low rates of eyelid ptosis and high satisfaction, especially among millennials.

• Evolysse Form and Smooth achieved non-inferiority and statistical superiority at 6 months vs. Restylane-L in US pivotal trials for nasolabial folds, with similar safety profiles.

• Evolysse Sculpt for mid-face volume showed non-inferiority to Restylane Lyft, with high responder rates and mild, transient adverse events.

• Profhilo is widely adopted in Europe, with high satisfaction among healthcare providers and patients, and offers a unique benefit for skin quality.

Innovation and technology

• Evolysse is the first major HA gel innovation in a decade, leveraging Cold-X technology for improved gel properties.

• Symatese, the manufacturing partner, brings over 25 years of R&D and biomaterials expertise, with a history of successful partnerships and product launches.

• Jeuveau uses HiPure manufacturing for precise, consistent outcomes.